Latest Commercialization News

Eastern Resources has secured a farm-in agreement to earn up to 80% interest in Queensland’s Marengo Gold Project, boasting impressive historic gold and copper grades. Meanwhile, lithium anomalies at its Trigg Hill project hint at further exploration potential.

Elixir Energy is set to resume production testing at its Diona-1 well this quarter and prepare for the high-impact Lorelle-3 appraisal well drilling in January 2026, aiming to unlock significant gas resources in Queensland’s Taroom Trough.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Whitebark Energy’s fresh petrophysical analysis reveals significant dry gas zones in its Warro Gas Field, boosting its commercial prospects and prompting a $750,000 capital raise to fast-track development.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

1414 Degrees has completed key milestones on its SiBox technology, advanced SiBrick storage media towards mass production, and acquired an exclusive licence for innovative silicon nanoparticle tech, backed by a $1.214 million capital raise.

Cullen Resources has secured key tenements and begun drilling at its Yardilla Gold Project while completing a A$1.5 million sale of its Wyloo Iron Ore Royalty, bolstering its exploration funding.

Ionic Rare Earths advances its global rare earths strategy with significant UK government funding, increased heavy rare earth oxide production, and a $15.6 million capital raise backed by a strategic US investor.

Archer Materials has successfully demonstrated that its blood potassium Biochip can be fabricated on a silicon platform, matching clinical accuracy standards and accelerating its path to commercialisation.

Pursuit Minerals progresses its Rio Grande Sur lithium project with a refined commercial plan and feasibility study, while expanding into gold through the Sascha Marcelina acquisition. A recent $4 million placement strengthens its financial position for growth.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.